General description

An orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC₅₀ in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn²⁺. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Hansen, H.P., et al. 2002. Int. J. Cancer98, 210.Tsuji, F., et al. 2002. Cytokine17, 294.Barlaam, B., et al. 1999. J. Med. Chem.42, 4890.Whittaker, M., et al. 1999. Chem. Rev.99, 2735.Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther.75, 69.

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)